Avalo Therapeutics, Inc.
AVTX$13M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWAYNE23 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 15, 2026
5wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 1 past
Phase 2Next
AVTX-009 Regimen 1 Phase 2 Results Expected
March 2026~AVTX-009 Regimen 1250
Primary completion for AVTX-009 Regimen 1 trial (NCT06603077) in Hidradenitis Suppurativa
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
FP01
Chronic Refractory Cough
AVTX-002
Non-Eosinophilic Asthma
CERC-301
Major Depressive Disorder
AVTX-009 Regimen 1
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
FP01 | Phase 2 | Chronic Refractory Cough | - |
AVTX-002 | Phase 2 | Non-Eosinophilic Asthma | - |
CERC-301 | Phase 2 | Major Depressive Disorder | - |
AVTX-009 Regimen 1 | Phase 2 | Hidradenitis Suppurativa | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
AVTX News